Evidence map›Paper›PMID 33794318›Full record

ArticleBioorganic & medicinal chemistry letters2021

Design and synthesis of C-aryl angular luotonins via a one-pot aza-Nazarov-Friedlander sequence and their Topo-I inhibition studies along with C-aryl vasicinones and luotonins.

Sivappa Rasapalli, Vamshikrishna Reddy Sammeta, Zachary F Murphy, James A Golen, Keli Agama, Yves Pommier, Sergey N Savinov

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Quinazolines [Molecules (Basel, Switzerland) · 2025
    Review
  3. Recent Advances in the Research on Luotonins A, B, and E.Molecules (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sivappa RasapalliUniversity of Massachusetts Dartmouth, Department of Chemistry and Biochemistry, 285 Old Westport Rd, North Dartmouth, MA 02747, USA. Electronic address: srasapalli@umassd.edu.
Vamshikrishna Reddy SammetaUniversity of Massachusetts Dartmouth, Department of Chemistry and Biochemistry, 285 Old Westport Rd, North Dartmouth, MA 02747, USA.
Zachary F MurphyUniversity of Massachusetts Dartmouth, Department of Chemistry and Biochemistry, 285 Old Westport Rd, North Dartmouth, MA 02747, USA.
James A GolenUniversity of Massachusetts Dartmouth, Department of Chemistry and Biochemistry, 285 Old Westport Rd, North Dartmouth, MA 02747, USA.
Keli AgamaDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-4255, USA.
Yves PommierDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-4255, USA.
Sergey N SavinovDepartment of Biochemistry and Molecular Biology, UMass Amherst, Amherst, MA 01003, USA.

Funding

DNA Topoisomerases as Target of Action of Anticancer DrugsZIABC006161 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 2009 to 2025
$16.8M
DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGSZ01BC006161 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.5M
Intramural NIH HHS Z01 BC006161
6 · The paper itself

Abstract

A facile one-pot synthesis of C-ring substituted angular luotonins has been realized via a methanesulfonic acid mediated aza-Nazarov-Friedlander condensation sequence on quinazolinonyl enones. Topoisomerase I (topo-I) inhibition studies revealed that the angular luotonin library (7a-7l) and their regioisomeric analogs (linear luotonins, 8a-8l) are weak negative modulators, compared to camptothecin. These results would fare well for the design of topo-I-inert luotonins for non-oncological applications such as anti-fungal and insecticide lead developments. Surprisingly, the tricyclic vasicinones (9h, 9i, and 9j) showed better topo-I inhibition compared to pentacyclic C-aryl luotonins providing a novel pharmacophore for further explorations.

Indexed as

Drug DesignAlkaloidsDNA Topoisomerases, Type IDose-Response Relationship, DrugHumansMolecular StructurePyrrolesQuinonesStructure-Activity RelationshipTopoisomerase I InhibitorsAlkaloidsDNA Topoisomerases, Type Iluotonin APyrrolesQuinonesTOP1 protein, humanTopoisomerase I Inhibitorsvasicinoneaza-NazarovQuinazolinonyl enonesTopoisomerase Iuotonin AVasicinone

Identifiers

PMID33794318
PMCPMC8113096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.